Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24. Oktober 2024 09:54 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
08. Februar 2024 15:17 ET
|
Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
01. November 2023 14:55 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$13.1 Bn by 2032 at a CAGR 1% | According PMR
20. Dezember 2022 08:10 ET
|
Persistence Market Research
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
28. Juli 2022 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
The Worldwide Anti-Vascular Endothelial Growth Factor Therapeutics Industry is Expected to Reach $13.3 Billion by 2030
03. Juni 2022 06:58 ET
|
Research and Markets
Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50
17. Oktober 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50
01. August 2012 09:15 ET
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Aug 1, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") and raised its...
Vista Partners Initiates Coverage on Ohr Pharmaceutical, Inc.; Target Price $2.20
17. April 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Apr 17, 2012) - Vista Partners announced today that it has initiated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...